Fig. 3From: CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinomaKaplan–Meier survival analysis. A Overall survival analysis based on ESCC clinical data from TCGA. B CD22 expression and overall survival analysis based on 87 cases of esophageal squamous cell carcinoma. No correlation between OS and CD22 expression was observedBack to article page